IndustryCompany release

Allarity wins first paid contract for new CLIA-certified laboratory services business

🇺🇸 Allarity Therapeutics, Inc. (ALLR) · Mon 02 Nov 2026

The Danish-based oncology company will develop and validate a European biotech's precision oncology predictive device for US use, after its Hørsholm lab gained CLIA certification in July.

Allarity Therapeutics announced on 30 October 2026 its first revenue-generating agreement under its CLIA laboratory services strategy. The company launched the strategy after its laboratory in Hørsholm received CLIA certification in July 2026.

Under the agreement, Allarity will provide development and validation services for a predictive device built by a European biotech. The device is a precision oncology product intended for use in the United States. The company has not been named in the information available, and no financial terms were provided.

Allarity says the new services business does not change its main development focus. Stenoparib, its dual PARP/WNT inhibitor, remains the top priority. The drug is in Phase 2 development for ovarian cancer and small cell lung cancer.

For context, CLIA refers to the US Clinical Laboratory Improvement Amendments, the framework under which laboratories that test human samples in the US must be certified.

What it means for your team

  • Sponsors and diagnostics developers planning US use of predictive oncology devices may find European labs with CLIA certification a route to validation work.
  • Quality teams should check that any outsourced validation lab holds the right CLIA certification for the intended US use.
  • Allarity's stated priority remains stenoparib, so the lab services business is presented as additional to, not a replacement for, its drug development.

Company's press release (SEC filing): Allarity Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Allarity Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →